Skip to main content
. 2019 Dec 3;10(64):6870–6878. doi: 10.18632/oncotarget.27326

Table 2. Estimated risk of subsequent serous carcinoma by serous borderline tumor gene mutation.

Gene mutation Total number of women Number of women with subsequent serous carcinoma Estimated median time to progression† (years) HR (95% CI)* p-value
Wildtype 54 12 9.2 1.00 -
BRAF 52 22 19.7 0.27 (0.08 – 0.93) 0.038
KRAS 95 5 14.4 1.00 (0.45 – 2.23) 0.99

time to progression derived using the Aalen-Johansen estimator.

*adjusted for age and stage (i.e. presence/absence of implants).